Blockers of the sars-cov-2 3a channel identified by targeted drug repurposing

Prabhat Pratap Singh Tomar, Miriam Krugliak, Isaiah T. Arkin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The etiological agent of the COVID-19 pandemic is SARS-CoV-2. As a member of the Coronaviridae, the enveloped pathogen has several membrane proteins, of which two, E and 3a, were suggested to function as ion channels. In an effort to increase our treatment options, alongside providing new research tools, we have sought to inhibit the 3a channel by targeted drug repurposing. To that end, using three bacteria-based assays, we screened a library of 2839 approved-for-human-use drugs and identified the following potential channel-blockers: Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine and Fludarabine. The stage is now set for examining the activity of these compounds in detailed electrophysiological studies and their impact on the whole virus with appropriate biosafety measures.

Original languageAmerican English
Article number532
Issue number3
StatePublished - 23 Mar 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


  • Antiviral drugs
  • Bacterial assays
  • Channel blockers
  • Viral channels


Dive into the research topics of 'Blockers of the sars-cov-2 3a channel identified by targeted drug repurposing'. Together they form a unique fingerprint.

Cite this